Results 51 to 60 of about 30,146 (272)
Újdonságok, aktualitások a polycythaemia vera diagnosztikájában és kezelésében | Diagnosis and treatment of polycythaemia vera: state of the art [PDF]
Absztrakt A polycythaemia vera a Philadelphia-negatív krónikus myeloid neoplasiák közé tartozó ritka neoplasia, amelyre az emelkedett vörösvérsejttömeg okozta hiperviszkozitás a jellemző.
Borbényi, Zita +2 more
core +1 more source
Using iPSC‐derived motoneurons and postmortem tissue from FUS‐ALS patients, it is demonstrated that increased mitochondrial transcription leads to elevated cytosolic double‐stranded RNA (dsRNA) levels. This aberrant accumulation activates a RIG‐I–dependent innate immune response leading to neurodegeneration, which is amenable for FDA‐ and EMA‐approved ...
Marcel Naumann +26 more
wiley +1 more source
Ruxolitinib stopped before transplantation does not induce cytokine release in myelofibrosis
Myelofibrosis (MF) is a myeloproliferative neoplasm characterized by marrow fibrosis, splenomegaly, constitutional symptoms and cytopenia with a proinflammatory and profibrotic cytokine phenotype involving the JAK-STAT pathway.
Sara Villar +15 more
doaj +1 more source
Tumor innate immunity primed by specific interferon-stimulated endogenous retroviruses. [PDF]
Mesenchymal tumor subpopulations secrete pro-tumorigenic cytokines and promote treatment resistance1-4. This phenomenon has been implicated in chemorefractory small cell lung cancer and resistance to targeted therapies5-8, but remains incompletely ...
A Marusyk +75 more
core +1 more source
Wedelolactone (WED), a natural TLR2 agonist, promotes neutrophil differentiation and enhances bactericidal function, offering a potential therapeutic strategy for neutropenia. Using a multi‐omics approach, this study reveals that WED activates the TLR2/MEK/ERK pathway, upregulating key transcription factors (PU.1, CEBPβ) to drive neutrophil development.
Long Wang +16 more
wiley +1 more source
T cell‐specific Socs1 knockout leads to inflammatory differentiation of CD8+ T cells, prompting the STAT1/2 complex to drive the activation of Ccl5, Ccr5, and Cxcr3, and promoting the skewing of monocytes toward a pro‐inflammatory M1 macrophage lineage.
Zhigui Wu +14 more
wiley +1 more source
RvD5 effectively alleviates UC by inhibiting STAT1 signaling to reduce CXCL8 expression in colonic epithelial cells via activation of GPR101, which subsequently decreases the infiltration of neutrophils in the colonic mucosal epithelium. Epimedin A1, a natural allosteric inhibitor of 5‐LOX, demonstrates potential as a therapeutic agent for UC by ...
Pengxiang Guo +9 more
wiley +1 more source
JAK3 as an emerging target for topical treatment of inflammatory skin diseases [PDF]
The recent interest and elucidation of the JAK/STAT signaling pathway created new targets for the treatment of inflammatory skin diseases (ISDs). JAK inhibitors in oral and topical formulations have shown beneficial results in psoriasis and alopecia ...
Alves de Medeiros, Ana +5 more
core +2 more sources
Cell‐Free DNA‐Based Theranostics for Inflammatory Disorders
Summary on the dual potential of cfDNA as biomarkers and therapeutic targets for inflammatory disorders. Figure was created with BioRender.com. ABSTRACT Inflammatory disorders are characterized by immune‐mediated inflammatory cascades that can affect multiple organs.
Jiatong Li +7 more
wiley +1 more source
BackgroundRuxolitinib has been approved by the US FDA for the treatment of myeloproliferative neoplasms such as polycythemia vera and primary myelofibrosis.
Sivahari P. Gorantla +7 more
doaj +1 more source

